Rockwell Medical Reports $17.3 Million in Net Sales, 8% Decrease in Q1 2026

Rockwell Medical, Inc. reported a net sales figure of $17.3 million for the first quarter of 2026, a decrease of 8% from $18.9 million in the same period of 2025. The decline in revenue was primarily attributed to a significant reduction in sales to DaVita, which fell by $3.9 million, including a prior price adjustment of $0.9 million that did not recur in 2026. This decrease was partially offset by a $2.6 million increase in sales from price adjustments to other existing customers and new customer acquisitions. The company recorded a gross profit of $2.9 million, down from $3.0 million a year earlier, resulting in a gross margin of 17% compared to 16% in the previous year.

In terms of operational performance, Rockwell Medical's total current assets decreased to $36.9 million as of March 31, 2026, from $38.2 million at the end of 2025. The company's cash and cash equivalents also saw a decline, falling to $9.6 million from $10.7 million. Total liabilities increased to $21.6 million, up from $20.2 million, primarily due to a rise in accounts payable and lease liabilities. The company reported a net loss of $1.6 million for the quarter, slightly higher than the $1.5 million loss recorded in the same quarter of the previous year.

Strategically, Rockwell Medical has focused on expanding its customer base and enhancing its product offerings. The company serves approximately 300 customers, including major dialysis providers like Fresenius and DaVita. Rockwell has also entered into an Amended and Restated Products Purchase Agreement with DaVita, which has been extended through December 31, 2026, with an increase in product pricing. This agreement is crucial as DaVita previously indicated plans to transition to another supplier, although discussions are ongoing.

Operationally, Rockwell Medical has made significant strides in its manufacturing capabilities, upgrading equipment to improve production efficiency and margins. The company has also implemented cost containment measures and renegotiated pricing with key suppliers. As of March 31, 2026, Rockwell's employee headcount remained stable, supporting its operational needs as it navigates the challenges of the hemodialysis market.

Looking ahead, Rockwell Medical's management believes it has sufficient liquidity to meet operational requirements for at least the next twelve months, with approximately $23.9 million in cash, cash equivalents, and investments available for sale. However, the company acknowledges the potential need for additional capital to sustain operations and execute its strategic plans, particularly in light of the uncertain macroeconomic environment. The company remains committed to enhancing its market position and achieving sustainable profitability through strategic customer partnerships and operational efficiencies.